Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded at Oppenheimer

Oppenheimer upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS - Free Report) from a market perform rating to an outperform rating in a research note released on Monday morning, Marketbeat.com reports. They currently have $6.00 target price on the biopharmaceutical company's stock.

Get MRNS alerts:

Several other equities research analysts have also issued reports on the stock. LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a report on Wednesday, August 14th. Truist Financial restated a buy rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Cantor Fitzgerald reiterated an overweight rating and issued a $13.00 price target on shares of Marinus Pharmaceuticals in a research note on Monday, September 16th. StockNews.com raised Marinus Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, September 18th. Finally, HC Wainwright reissued a buy rating and issued a $11.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus target price of $8.83.

Ad Porter & Company

My grim warning about AI stocks

Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.

So go here now to read my new report The Big AI Die-Up… while you still can.

Get Our Latest Stock Report on MRNS

Marinus Pharmaceuticals Stock Performance

Shares of MRNS traded down $0.03 during trading hours on Monday, hitting $1.63. The stock had a trading volume of 1,144,921 shares, compared to its average volume of 1,125,639. Marinus Pharmaceuticals has a 12 month low of $1.05 and a 12 month high of $11.26. The stock has a fifty day moving average price of $1.38 and a 200 day moving average price of $2.73. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15. The firm has a market capitalization of $89.54 million, a PE ratio of -0.62 and a beta of 1.13.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The company had revenue of $8.06 million for the quarter, compared to analysts' expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter last year, the firm posted ($0.61) earnings per share. Analysts anticipate that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC increased its position in Marinus Pharmaceuticals by 31.4% during the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company's stock valued at $37,431,000 after acquiring an additional 990,607 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Marinus Pharmaceuticals in the second quarter worth about $813,000. Renaissance Technologies LLC purchased a new position in shares of Marinus Pharmaceuticals during the second quarter valued at approximately $727,000. Superstring Capital Management LP bought a new position in shares of Marinus Pharmaceuticals during the fourth quarter valued at approximately $5,027,000. Finally, XTX Topco Ltd purchased a new stake in shares of Marinus Pharmaceuticals in the second quarter worth approximately $232,000. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Company Profile

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Should you invest $1,000 in Marinus Pharmaceuticals right now?

Before you consider Marinus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Marinus Pharmaceuticals wasn't on the list.

While Marinus Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Unlock the Potential in Options Trading

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report